SOURCE-LINKED STUDY SUMMARY
Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.
Abstract summarizedQuality not appraised
- What was studied
- An animal study compared MitoQ and SS-31 (elamipretide) for mitochondrial function, oxidative stress and liver injury in diet-induced fatty liver disease.
- Who / model studied
- Female C57BL/6 mice aged 12–14 months received a high-fat, high-fructose diet for 16 weeks to induce MASLD.
- Studied dose & schedule
- Randomized groups included control diet, untreated MASLD, oral MitoQ at 25 mg/kg/day, or intraperitoneal SS-31 at 3 mg/kg/day. Drug-treatment duration was not separately specified.
- What the study found
- Both treatments improved mitochondrial protein markers, reduced inflammatory signaling and liver fat, and increased insulin-signaling protein expression versus untreated MASLD mice. MitoQ primarily strengthened antioxidant defenses, whereas SS-31 better preserved mitochondrial structural integrity. These were mouse tissue and histology findings.
- Limitations & context
- Study limitations were not stated in the abstract. Methodological quality has not been appraised.
Read summary source ↗ · Prepared 9/24/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.